FDA Approves Opdivo Qvantig, a Subcutaneous Formulation of Nivolumab
14 hours ago · Noninferiority was also demonstrated for the secondary endpoint of objective response rate (ORR); ORR was 24% (95% CI, 19-30) in the Opdivo Qvantig group and 18% (95% CI, 14-24) in the IV ...
FDA Approves Subcutaneous Immunotherapy Opdivo Qvantig
1 day ago · The FDA has approved a new way to receive a cancer treatment called nivolumab (Opdivo). This new version, called Opdivo Qvantig, can be given as an injection under the skin instead of through an IV. This approval applies to many types of cancer where Opdivo is already used, including: Kidney cancer; Melanoma (skin cancer) Lung cancer; Head and ...
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab …
Dec 27, 2024 · OPDIVO ® (nivolumab), in combination with YERVOY ® (ipilimumab), is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
FDA Approves Subcutaneous Opdivo Qvantig for Most Solid …
5 days ago · Opdivo Qvantig is a combination product of nivolumab coformulated with recombinant human hyaluronidase. This approval is for most previously approved adult, solid tumor Opdivo indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy (ipilimumab) combination therapy, or in combination with chemotherapy or ...
FDA Approves Injectable Opdivo for Many Types of Cancer
5 days ago · “This approval of subcutaneous nivolumab gives our patients a new option that can deliver consistent efficacy and comparable safety expected from IV nivolumab and offers a patient-centric treatment experience,” Saby George, MD, of Roswell Park Comprehensive Cancer Center, said in a news release. “Opdivo Qvantig offers faster ...
FDA approves subcutaneous opdivo qvantig for most solid tumor …
4 days ago · The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo ...
Opdivo Qvantig Approved to Treat Solid Tumor Malignancies
6 days ago · FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection. News release. US Food and Drug Administration. Published December 27, 2024. Accessed December 31, 2024. OPDIVO QVANTIG ...
Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo …
Dec 30, 2024 · Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval for Opdivo Qvantig™ (nivolumab and ...
Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo …
Dec 30, 2024 · As a key powered secondary endpoint, the overall response rate (ORR) in the Opdivo Qvantig arm (n=248) was 24% (95% CI: 19-30) compared with 18% (95% CI: 14-24) in the IV Opdivo arm (n=247 ...
FDA Approves Nivolumab and Hyaluronidase-nvhy for …
6 days ago · On December 27, 2024, the U.S. Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult, solid tumor nivolumab indications as monotherapy, monotherapy maintenance following completion of nivolumab plus ipilimumab combination therapy, or in combination with chemotherapy or …
- Some results have been removed